Literature DB >> 33220806

Debate: Improvements in Systemic Therapies for Liver Metastases Will Increase the Role of Locoregional Treatments.

Yoshikuni Kawaguchi1, Mario De Bellis2, Elena Panettieri2, Gregor Duwe2, Jean-Nicolas Vauthey3.   

Abstract

The benefit of resection of liver metastases depends on primary diseases. Neuroendocrine tumors are associated with favorable prognosis after resection of liver metastases. Gastric cancer has worse tumor biology, and resection of gastric liver metastases should be performed in selected patients. A multidisciplinary approach is well established for colorectal liver metastases (CLMs). Resection remains the only curative treatment of CLM. Chemotherapy and molecular-targeted therapy have improved survival in unresectable metastatic colorectal cancer. Understanding of the following two strategies, conversion therapy and two-stage hepatectomy, are important to make this patient group to be candidates for curative-intent surgery.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Colorectal liver metastasis; Conversion therapy; Gastric liver metastasis; Molecular-targeted therapy; Neuroendocrine liver metastasis; Resection; Two-stage hepatectomy

Mesh：

Year:  2020        PMID： 33220806      PMCID： PMC7709757          DOI： 10.1016/j.soc.2020.08.009

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN： 1055-3207            Impact factor:   3.495


  65 in total

1.  A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.

Authors:  R Wong; D Cunningham; Y Barbachano; C Saffery; J Valle; T Hickish; S Mudan; G Brown; A Khan; A Wotherspoon; A S Strimpakos; J Thomas; S Compton; Y J Chua; I Chau
Journal:  Ann Oncol       Date:  2011-02-01       Impact factor: 32.976

2.  Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy.

Authors:  Scott Kopetz; George J Chang; Michael J Overman; Cathy Eng; Daniel J Sargent; David W Larson; Axel Grothey; Jean-Nicolas Vauthey; David M Nagorney; Robert R McWilliams
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544

3.  Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.

Authors:  Fotios Loupakis; Chiara Cremolini; Gianluca Masi; Sara Lonardi; Vittorina Zagonel; Lisa Salvatore; Enrico Cortesi; Gianluca Tomasello; Monica Ronzoni; Rosella Spadi; Alberto Zaniboni; Giuseppe Tonini; Angela Buonadonna; Domenico Amoroso; Silvana Chiara; Chiara Carlomagno; Corrado Boni; Giacomo Allegrini; Luca Boni; Alfredo Falcone
Journal:  N Engl J Med       Date:  2014-10-23       Impact factor: 91.245

4.  Expanded criteria for carcinoid liver debulking: Maintaining survival and increasing the number of eligible patients.

Authors:  Amanda N Graff-Baker; David A Sauer; SuEllen J Pommier; Rodney F Pommier
Journal:  Surgery       Date:  2014-11-11       Impact factor: 3.982

5.  Epidemiology and management of liver metastases from colorectal cancer.

Authors:  Sylvain Manfredi; Côme Lepage; Cyril Hatem; Olivier Coatmeur; Jean Faivre; Anne-Marie Bouvier
Journal:  Ann Surg       Date:  2006-08       Impact factor: 12.969

6.  Hepatic neuroendocrine metastases: does intervention alter outcomes?

Authors:  R S Chamberlain; D Canes; K T Brown; L Saltz; W Jarnagin; Y Fong; L H Blumgart
Journal:  J Am Coll Surg       Date:  2000-04       Impact factor: 6.113

7.  Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.

Authors:  Alfredo Falcone; Sergio Ricci; Isa Brunetti; Elisabetta Pfanner; Giacomo Allegrini; Cecilia Barbara; Lucio Crinò; Giovanni Benedetti; Walter Evangelista; Laura Fanchini; Enrico Cortesi; Vincenzo Picone; Stefano Vitello; Silvana Chiara; Cristina Granetto; Gianfranco Porcile; Luisa Fioretto; Cinzia Orlandini; Michele Andreuccetti; Gianluca Masi
Journal:  J Clin Oncol       Date:  2007-05-01       Impact factor: 44.544

8.  The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors.

Authors:  Anthony J Chambers; Janice L Pasieka; Elijah Dixon; Otto Rorstad
Journal:  Surgery       Date:  2008-10       Impact factor: 3.982

9.  Sequential preoperative ipsilateral hepatic vein embolization after portal vein embolization to induce further liver regeneration in patients with hepatobiliary malignancy.

Authors:  Shin Hwang; Sung-Gyu Lee; Gi-Young Ko; Bum-Soo Kim; Kyu-Bo Sung; Myung-Hwan Kim; Sung-Koo Lee; Hea-Nam Hong
Journal:  Ann Surg       Date:  2009-04       Impact factor: 12.969

10.  Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases.

Authors:  Eddie K Abdalla; Jean-Nicolas Vauthey; Lee M Ellis; Vickie Ellis; Raphael Pollock; Kristine R Broglio; Kenneth Hess; Steven A Curley
Journal:  Ann Surg       Date:  2004-06       Impact factor: 12.969
View more
  2 in total

Review 1.  Neoadjuvant Pelvic Radiotherapy in the Management of Rectal Cancer with Synchronous Liver Metastases: Is It Worth It?

Authors:  Maitham A Moslim; Amir L Bastawrous; D Rohan Jeyarajah
Journal:  J Gastrointest Surg       Date:  2021-06-07       Impact factor: 3.452

2.  A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT study.

Authors:  Masaru Matsumura; Kiyoshi Hasegawa; Masaru Oba; Kensei Yamaguchi; Hiroyuki Uetake; Takayuki Yoshino; Satoshi Morita; Keiichi Takahashi; Michiaki Unno; Yasuhiro Shimada; Kei Muro; Nobuhisa Matsuhashi; Masaki Mori; Hideo Baba; Mitsuo Shimada; Yoshihiro Mise; Yoshikuni Kawaguchi; Tatsuo Kagimura; Kiyoshi Ishigure; Akio Saiura; Kenichi Sugihara; Norihiro Kokudo
Journal:  Langenbecks Arch Surg       Date:  2022-02-25       Impact factor: 2.895
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.